Cyclin-dependent kinase (CDK) 4/6 inhibition in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations
Conclusion: Combination therapy with CDK4/6 inhibitors and EGFR-TKIs may be a promising approach.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Drugs & Pharmacology | Genetics | Investigational New Drugs | Lung Cancer | Non-Small Cell Lung Cancer